Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company, is pleased to announce exciting new data from its Phase ...

Imugene is tapping the market for up to $35 million, while Clever Culture Systems and Compumedics are soaring on positive ...

A genetically diverse mouse model allowed researchers to identify genes that promote the success of immune checkpoint ...

Nurix Therapeutics shows strong BTK degrader data and key pharma ties, with risks but solid long-term potential. Find out why ...

前言在《CAR-T细胞治疗：系统性红斑狼疮的新希望？》一文中讨论了CAR-T细胞治疗红斑狼疮的原理。本篇接上文话题，讨论CAR-T细胞治疗的利弊。CAR-T细胞成功治疗红斑狼疮的著名研究案例1 德国Georg Schett团队德国Georg ...